Trial Profile
Inotuzumab Ozogamicin - PF-05208773
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 19 May 2020
Price :
$35
*
At a glance
- Drugs Inotuzumab ozogamicin (Primary)
- Indications Burkitt's lymphoma; Chronic myeloid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Expanded access; Therapeutic Use
- Sponsors Pfizer
- 14 May 2020 Status changed from recruiting to completed.
- 27 Apr 2017 New trial record